Tealwood Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.47M | Sell |
11,710
-14
| -0.1% | -$1.76K | 0.66% | 75 |
|
|
2025
Q1 | $1.3M | Sell |
11,724
-187
| -2% | -$20.7K | 0.6% | 82 |
|
|
2024
Q4 | $1.63M | Buy |
11,911
+118
| +1% | +$16.1K | 0.67% | 68 |
|
|
2024
Q3 | $1.36M | Sell |
11,793
-106
| -0.9% | -$12.2K | 0.6% | 84 |
|
|
2024
Q2 | $1.64M | Sell |
11,899
-109
| -0.9% | -$15K | 0.99% | 43 |
|
|
2024
Q1 | $1.66M | Sell |
12,008
-247
| -2% | -$34.1K | 0.75% | 59 |
|
|
2023
Q4 | $1.62M | Sell |
12,255
-219
| -2% | -$28.9K | 0.77% | 54 |
|
|
2023
Q3 | $1.4M | Sell |
12,474
-361
| -3% | -$40.6K | 0.72% | 60 |
|
|
2023
Q2 | $1.21M | Sell |
12,835
-219
| -2% | -$20.6K | 0.59% | 87 |
|
|
2023
Q1 | $1.32M | Buy |
13,054
+29
| +0.2% | +$2.94K | 0.67% | 65 |
|
|
2022
Q4 | $1.56M | Sell |
13,025
-1,146
| -8% | -$137K | 0.81% | 46 |
|
|
2022
Q3 | $1.51M | Sell |
14,171
-23
| -0.2% | -$2.44K | 0.81% | 44 |
|
|
2022
Q2 | $1.38M | Sell |
14,194
-402
| -3% | -$39.2K | 0.69% | 54 |
|
|
2022
Q1 | $1.37M | Buy |
14,596
+9,399
| +181% | +$881K | 0.58% | 77 |
|
|
2021
Q4 | $443K | Sell |
5,197
-7,034
| -58% | -$600K | 0.18% | 122 |
|
|
2021
Q3 | $1.17M | Buy |
+12,231
| New | +$1.17M | 0.47% | 109 |
|
|
2021
Q1 | $1.25M | Buy |
12,799
+646
| +5% | +$62.8K | 0.5% | 103 |
|
|
2020
Q4 | $1.17M | Buy |
12,153
+6,131
| +102% | +$588K | 0.55% | 92 |
|
|
2020
Q3 | $579K | Buy |
+6,022
| New | +$579K | 0.38% | 80 |
|